In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
400 News Items found
Pedram Razavi, Jorge Reis-Filho, and Bob Li
Finding
Many Mutations Detected in Liquid Biopsy Tests Do Not Come from Cancer Cells, an MSK Study Finds

The new findings suggest the need for caution when interpreting the results from these tests.
Michael Postow, Nitya Raj and Triparna Sen
MSK Leaders Recognized in the 40 Under 40 in Cancer Class of 2020

Chief of the Melanoma Service Michael Postow, MD, Medical Oncologist Nitya Raj, MD, and Assistant Attending Triparna Sen, PhD were included on this year’s list.
Molecular biologist John Petrini of the Sloan Kettering Institute.
Feature
Understanding the DNA-Damage “First Responders”: John Petrini at Work

Scientists know that cancer can result from mistakes in DNA repair. But understanding what controls the repair process itself has been a hard nut to crack.
Group photo of researchers Michael Berger, Marc Ladanyi, Dana Tsui, Rose Brannon, Ryma Benayed, Ahmet Zehir, and David Klimstra.
Feature
How MSK-ACCESS Blood Test for Cancer was Created

MSK-ACCESS, a blood test that can detect mutations in 129 genes related to cancer, has already helped guide the treatment of more than 2,800 patients at MSK.
Nat, Alex, and Michael Wolff and Polly Draper
Fixing One Wrong Note: How MSK Precision Diagnostics Saved a Musician With a Rare Cancer

Learn how molecular testing and an experimental targeted therapy cured jazz musician Michael Wolff, who had the rare cancer histiocytic sarcoma.
MSK medical oncologist Alexander Drilon
Feature
First Targeted Cancer Drug Approved Based on Mutation Rather than Tumor Type

Learn about larotrectinib, the first cancer drug to be FDA approved for adult and pediatric patients at the same time.
Memorial Sloan Kettering Collaborates with Global Community on the Bloomberg New Economy International Cancer Coalition to Accelerate and Expand Access to New Therapies and Clinical Trials

The Coalition was discussed at the fourth annual Bloomberg New Economy Forum (NEF) in Singapore on November 16–19.
SKI scientists David Scheinberg and Derek Tan
Sloan Kettering Institute Scientists Retool CAR T Cells to Serve as ‘Micropharmacies’ for Cancer Drugs

These souped-up versions may help overcome some limitations of existing CAR T cells.
Andy Minn and Michael Glickman
Tackling Immunotherapy’s Big Challenges

Learn why immuno-oncology — which seeks to rally and strengthen the immune system’s ability to fight cancer — is the world’s next frontier in cancer research, and how MSK is overcoming some of the field's biggest challenges.
Microscopy image showing a quiescent cluster of lung adenocarcinoma tumor cells with low STING expression.
MSK Scientists Identify Potential New Strategy Against Metastasis

A team of scientists at the Sloan Kettering Institute has identified the STING cellular signaling pathway as a key player in keeping dormant cancer cells from progressing into aggressive tumors months, or even years, after they’ve escaped from a primary tumor.